The QualityStocks Daily Monday, June 11th, 2018

Today's Top 3 Investment Newsletters


QualityStocks (RGUS) +40.65%

MarketBeat (CTDH) +33.33%

The QualityStocks Daily Stock List

Identillect Technologies Corp. (IDTLF)

Stock News Now, StockPicksNYC, and SeeThruEquityResearch reported earlier on Identillect Technologies Corp. (IDTLF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Identillect Technologies Corp. is a foremost provider of SaaS (Software as a Service) email security. The Company’s Delivery Trust™ email security technology platform enables individuals and businesses of all sizes a cost-effective way to create a more secure digital environment and protect against cyber security risks.  Identillect Technologies has its corporate office in Irvine, California.

Delivery Trust™ is the industry’s simplest plug and play security solution. It is an award -winning, multi-platform plug-in, which gives users total control of their emails, for one low price. Delivery Trust™ is available for iPhone®, iPad®, Android, Windows, and Mac PC's and Laptops and the web's most popular email platforms. 

Delivery Trust™  has a wide range of features. These include state-of-the-art encryption technology, restricting email forwarding and printing, receipt confirmation, limiting time available to view, and also retracting sent emails.

Identillect Technologies has a service collaboration with the National Association of Professional Agents (NAPA), providing NAPA members access to the Company's set of compliance tools. This includes the Identillect Delivery Trust™ email encryption service. NAPA specializes in building custom company-sponsored E&O and benefit programs tailored to meet the unique requirements of a sponsoring company’s distribution force.

Last month, Identillect Technologies announced a joint project with QubeChain LLC to provide Multi-Factor Authentication (MFA) with its Self-Sovereign ID (SSI) platform, an enhanced level of security for organizations at higher risk or with advanced security demands. QubeChain is built to promote transformation by taking advantage of creative innovation and deep industry expertise to produce Applied Uses of Blockchain Technology across all industries.

Last week, Identillect Technologies announced excellent growth for 2017. Subscriber growth saw increases of 56 percent over prior subscriber base numbers.

Mr. Todd Sexton, Identillect Technologies’ Chief Executive Officer, stated, "Identillect is excited about the growth we have seen in 2017, advancements in the technology of Delivery Trust will continue to motivate new industries utilizing our products to prevent security breaches within their businesses. The growth in cloud service offerings along with the need for blockchain technologies makes Delivery Trust the ideal product for organizations spanning almost every industry to advance their security protocols.”

Yesterday, Identillect Technologies announced the launch of a multi-faceted digital campaign to the legal community using the legal marketing specialists at Market My Market. Identillect chose the legal marketing specialists at Market My Market to boost multi-avenue digital campaigns to legal professionals throughout the country.

Identillect’s campaigns with Market My Market to the U.S. population of greater than 1.3 million lawyers and many state bar associations’ aims to further solidify the Company’s Delivery Trust® as the email security solution of choice for professionals in the legal community.

Identillect Technologies Corp. (IDTLF), closed Monday's trading session at $0.067, up 5.02%, on 108,292 volume with 18 trades. The average volume for the last 60 days is 41,560 and the stock's 52-week low/high is $0.0464/$0.4763.

Kush Bottles, Inc. (KSHB)

StreetAuthority Daily, CFN Media Group, Stock News Now, The Street,   Promotion Stock Secrets, and SmallCapVoice reported  on Kush Bottles, Inc. (KSHB), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Kush Bottles, Inc. is a sales and distribution platform that provides packaging, supplies, vaporizers, accessories, and branding solutions for the regulated cannabis industry. The Company provides certified child-resistant and custom-branded solutions in all States that permit medical or recreational cannabis use. Kush Bottles is the only marijuana packaging company with manifold full-service facilities across the United States.

The Company has its headquarters and California fulfillment center in Santa Ana, California. Kush Bottles now regularly services more than 5,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe. The Company has also opened a new Product Development and Genomics Lab in San Diego, California to produce unique terpene formulations.

Kush Bottles provides pop top bottles; child resistant exit, paper exit, and foil barrier bags; tubes; and polystyrene, polypropylene, or silicone containers to urban farmers, greenhouse growers, and medical and recreational cannabis dispensaries. The Company centers on providing the highest quality medical and food grade packaging.   Kush Bottles also centers on selecting products that are environmentally friendly and manufactured within the U.S.

In 2017, Kush Bottles acquired CMP Wellness, LLC  (Los Angeles, California). CMP is a privately held distributor of vaporizers, cartridges, and accessories. In addition, Kush acquired the web domain This is an online distribution platform for retail sales of collapsible and unbreakable medical-grade silicone water pipes.

Kush Bottles has launched the marijuana industry's first online system. The system enables customers to design custom-branded packaging solutions. The tool makes it easier for customers to place orders. The expectation is that this will lead to a higher conversion rate and a better Return on Investment  (ROI).

Kush Bottles launched a Food and Drug Administration (FDA) compliant Kush Canister™ to safely and securely store cannabis products for resale purposes. The canister can fit just over one ounce of cannabis flower. The canister has a certified child resistant push-top to comply with regulations in the States that necessitate child resistant packaging.

In early May, Kush Bottles announced it completed its acquisition of Summit Innovations, LLC. Summit Innovations was acquired in exchange for 1,280,000 shares of Kush Bottles common stock and roughly $3.2 million in cash, subject to certain adjustments and holdbacks. Summit Innovations (based in Denver, Colorado) is a foremost distributor of hydrocarbons to the legal cannabis industry.

At the end of May, Kush Bottles announced it signed a lease for a new warehouse facility in Las Vegas, Nevada. This is to meet demand from the consumer market and also support the current and new businesses entering the industry or expanding operations.

Last week, Kush Bottles announced it launched a new division, Koleto Packaging Solutions. This division will bring new, FDA-compliant packaging solutions to the pharmaceutical and veterinary industries. Mr. Edd Pratt, Executive Vice President, will run this division. The expectation is that Koleto Packaging Solutions will serve pharmaceutical companies and veterinary clinics throughout the U.S.

Kush Bottles, Inc. (KSHB), closed Monday's trading session at $5.43, down 1.27%, on 930,942 volume with 1,746 trades. The average volume for the last 60 days is 412,453 and the stock's 52-week low/high is $1.81/$8.51.

Delcath Systems, Inc. (DCTH)

OTC Markets, StocksGallery, 4-Traders, Barchart, Invest, Morningstar, Stock News Journal, Stocktwits, SuperStockScreener, TradingView, MarketWatch, and Insider Financial reported on Delcath Systems, Inc. (DCTH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. The Company’s investigational product is Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The design of this product is to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Delcath Systems is based in New York, New York.

The Company has supported clinical research of liver directed high dose chemotherapy in patients with metastatic ocular and cutaneous melanoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and hepatocellular carcinoma.  Its system has been commercially available in Europe since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide variety of cancers of the liver. Liver directed high dose chemotherapy uses percutaneous hepatic perfusion (PHP) to deliver concentrated doses of a chemotherapeutic agent directly to the liver.

Delcath Systems is working on advancing its clinical programs of its innovative Melphalan/HDS. Additionally, it is working to boost commercialization efforts for CHEMOSAT in Europe. The Company continues its emphasis on the clinical trials that comprise the Clinical Development Program (CDP).

Delcath Systems has started a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM). Delcath plans to initiate a global registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration  (FDA) for sale in the U.S. 
Delcath Systems announced in February 2018 that physicians in Europe performed the 500th PHP Therapy® treatment employing Delcath’s Hepatic CHEMOSAT® Delivery System (CHEMOSAT). Physicians in select European markets have used CHEMOSAT to treat a wide spectrum of cancers of the liver.

Delcath Systems announced this past March that it entered into a commercial supply agreement with Tillomed Laboratories, an EMCURE company, for the procurement of melphalan for use with Delcath Systems’ Hepatic CHEMOSAT® Delivery System for Melphalan. Luton, Bedfordshire (UK) based, Tillomed Laboratories specializes in the licensing, marketing and supply of generic and branded pharmaceutical products to hospitals, wholesalers and pharmacists nationwide.

Last month, Delcath Systems announced that it initiated its pivotal trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC). Duke Medical Center in Durham, North Carolina is the first cancer center to open for patient enrolment.   Dr. Sabino Zani is serving as the principal investigator for the trial in the U.S. Dr. Zani is a surgical oncologist with Duke Medical Center.

In addition, in May, Delcath Systems announced that the German Guidelines Program in Oncology (GGPO) has included treatment with the Company’s CHEMOSAT® in the German national treatment guidelines for liver metastases from melanoma. This inclusion of treatment with CHEMOSAT is in the S3 Guidelines. This represents the highest level within the classification of the guidelines indicating that it is based on evidence and consensus within the German clinical community.

Delcath Systems, Inc. (DCTH), closed Monday's trading session at $3.21, down 1.83%, on 4,977 volume with 78 trades. The average volume for the last 60 days is 1,604 and the stock's 52-week low/high is $1.22/$63,857.50.

Avita Medical Limited (AVMXY)

Zacks, Amigo Bulls, Speculating Stocks, Marketbeat, OTC Markets, The Street, The StreetWise Reports, TradingView, InvestorsHub, MarketWatch, Stockhouse,, StreetInsider, Marketwired, Penny Stock Picks, HotCopper, Business Insider, GuruFocus, WalletInvestor, 4-Traders, and Edison Investment Research reported on Avita Medical Limited (AVMXY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A medical device company, Avita Medical Limited provides an innovative approach to skin regeneration. The Company’s products are for the treatment of a broad spectrum of wounds, scars, as well as skin defects. These products are presently available directly in the United Kingdom (UK), Germany, Australia and New Zealand and around the world through distributors in France, Belgium, Netherlands, Turkey, China, Malaysia, Taiwan, Iran and South Africa.

Avita Medical operates from offices in Wimbledon, UK; Valencia, California, and Perth, Australia. The Company lists on the OTCQX.

In all countries outside of Europe, Avita Medical’s portfolio is marketed under the ReCell® brand to promote skin healing in a broad array of applications. This includes burns, chronic wounds, as well as aesthetics. In the U.S., ReCell® is an investigational device limited by federal law to investigational and compassionate use.

Avita Medical’s patented and proprietary collection and application technology provides unique treatment solutions derived from the regenerative properties of a patient’s own skin. The Company’s medical devices work by preparing a Regenerative Epithelial Suspension (RES™). This is an autologous suspension consisting of the patients’ own skin cells and wound healing factors, which are essential to regenerate natural healthy skin. This is subsequently applied to the area to be treated.

In Europe, Avita Medical’s portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. These are ReCell®, ReGenerCell™, and ReNovaCell™.

The design of ReCell® is for the treatment of burns and plastic reconstructive procedures. ReGenerCell™ has been formulated for chronic wounds. This includes leg and foot ulcers. ReNovaCell™ is tailored for aesthetic applications. This includes the restoration of pigmentation.

This past April, Avita Medical announced that its pivotal, controlled clinical trial in the treatment of deep full-thickness (third-degree) burns with the RECELL® Autologous Cell Harvesting Device realized its co-primary endpoints, demonstrating a statistically significant reduction in donor skin requirements in comparison to standard of care while attaining comparable definitive wound closure. The results were presented at the American Burn Association (ABA) 50th Annual Meeting in Chicago, Illinois by James H. Holmes, IV, MD, FACS, Wake Forest Baptist Medical Center, Winston-Salem, North Carolina.

Last month, Avita Medical announced that results from a study validating the predicted outcomes and costs from an acute burns health economic model were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland.

The milestone model is the first validated economic model available to assess the costs and clinical impact of new interventions in comparison to standard of care for inpatient treatment of acute burns along the burn care continuum. The model demonstrates the ability to predict the cost-effectiveness, incremental costs and the budget impact of diverse care management approaches.

Last week, Avita Medical announced an institutional placement of A$16.0 million to prepare for the planned U.S. launch of the RECELL® Device in the treatment of severe burns. The Company received commitments from global and Australian institutional and sophisticated investors for a placement of A$16.0 million at an issue price of A$0.050 per share, with the placement to take place in two tranches.

Avita Medical Limited (AVMXY), closed Monday's trading session at $0.982, up 6.74%, on 104,170 volume with 62 trades. The average volume for the last 60 days is 30,993 and the stock's 52-week low/high is $0.75/$1.47.

Glance Technologies, Inc. (GLNNF)

InvestorsHub, MarketWatch, Evergreen Caller, and Emerging Growth reported on Glance Technologies, Inc. (GLNNF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Glance Technologies, Inc.  owns and operates Glance Pay. This is a streamlined payment system. Glance Pay  transforms how smartphone users choose where to dine, order food and  drink, settle bills, access digital receipts, earn first-rate rewards, and interact with merchants. With the Glance Pay mobile payment app,  there is no set up or cancellation fees and no system integration or connections needed. OTCQB-listed, Glance Technologies is based in Vancouver, British Columbia.

The Glance Pay mobile payment app works for full service restaurants, quick serve restaurants (QSRs), retail, and more. It also features easy activation and training, easy automatic accounting and reconciliation, and fast payment deposits. Servers and managers can review transaction details.

Glance Technologies is building a valuable network of merchants and consumers. The Company offers targeted in-app marketing, social media marketing, customer feedback, in-merchant messaging, and custom rewards programs.

The Glance Pay mobile payment system consists of proprietary technology. The technology includes user apps available for free downloads in IOS (Apple) and Android formats, a merchant manager app,  a large-scale technology hosting environment with sophisticated anti-fraud technology, and very fast payment processing.

Glance Technologies intends to apply elements of its anti-fraud technology to cryptocurrencies. This is to lessen the risk associated with converting traditional currencies to and from cryptocurrencies.

  Glance Technologies entered into a non-binding Letter of Intent (LOI) to acquire Blockimpact from Ztudium Limited. With the LOI, Glance will acquire all of the intellectual property (IP) consisting of the BlockImpact platform for US$1.1 million. BlockImpact is a complete end-to-end cryptocurrency blockchain solution. BlockImpact is a blockchain and cryptocurrency with a rewards tokenization platform.

Glance Technologies is pursuing opportunities to license its earlier acquired BlockImpact cryptocurrency and blockchain platform as a white label solution. The Company’s belief is that there is significant demand in the market for applications of this technology platform. Glance Technologies has had discussions with a number of parties interested in licensing the technology.

In mid-May, Glance Technologies announced that the current quarter was already the Company’s strongest ever for launches and merchant partner signings. It had signed 136 new locations and launched 50 new locations in 11 weeks since the current fiscal quarter began on March 1, 2018. This made it Glance’s best quarter to date for those metrics, and two weeks were still left to go in the quarter.

Last week, Glance Technologies’ partially-owned subsidiary, Cannapay Financial, announced a name change to The Yield Growth Corp. Yield Growth is moving beyond payment solutions. It is a cannabis asset growth company, which is creating high value products and services for the cannabis industry and its key players.

Glance Technologies, Inc. (GLNNF), closed Monday's trading session at $0.56277, up 6.38%, on 504,541 volume with 226 trades. The average volume for the last 60 days is 518,930 and the stock's 52-week low/high is $0.11/$3.20.

Nemaura Medical, Inc. (NMRD)

Market Exclusive, OTC Markets, and 4-Traders reported on Nemaura Medical, Inc. (NMRD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Nemaura Medical,  Inc. is a medical technology business listed on the NasdaqCM. The Company is developing the wireless sugarBEAT® disposable adhesive skin-patch as a non-invasive, needle-free, pain-free, and affordable continuous glucose monitoring (CGM) system for adjunctive use by diabetics. Nemaura Medical is based in Loughborough, England.

The Company’s patient-friendly technology has the potential to transform health monitoring through providing real-time, tailored feedback on glucose, lactate, and other vital body performance metrics.  Its patented  BEAT™  technology  (passing a mild, non-perceptible electric current across the skin)  draws a small number of selected molecules, such as glucose, into a patch placed on the skin.

These molecules are drawn out of the interstitial fluid. The patch  (by way of a sensor) measures the amount of that molecule present, converting it into a meaningful concentration value for clinical diagnosis or preliminary guidance for self-treatment. 

The BEAT™ technology will permit remote continuous monitoring of chronic diseases and health conditions. It is to replace traditional invasive methods of diagnosis and healthcare observation procedures.

The sugarBEAT® App can be pre-downloaded on a user’s smart device. There is an optional sugarBEAT® handheld reader (applicable where a user chooses not to use their own smart device).

sugarBEAT®  provides accurate glucose measurement.  sugarBEAT® comprises a reusable transmitter containing a daily-disposable adhesive skin-patch. 

Nemaura Medical announced at the end of January 2018 positive summary data for its sugarBEAT® European clinical trial program. The summary results were taken from a 25 patient cohort of the earlier reported European three-stage 75 patient Clinical study, consisting of 80 percent Type 1 and 20 percent Type 2 Diabetics.

Results indicate an overall MARD (Mean Absolute Relative Difference) of 13.76 percent over an extensive dynamic glucose concentration range. Up to 70 percent of the data from the study paired between sugarBEAT® and the venous blood glucose concentration achieved an average MARD of 10.28 percent, denoting even greater accuracy. No serious or major device related adverse events were noted. A MARD of 10 percent is considered to be sufficient for making therapeutic decisions.

Recently, Nemaura Medical announced that it entered into a definitive joint Collaboration Agreement with Dallas Burston Ethitronix (DBE) to commercialize sugarBEAT® in the European Economic Area (EEA). Nemaura Medical earlier signed a licensing agreement with DBE for the commercialization of sugarBEAT® in the United Kingdom (UK) and Ireland.

DBE and Nemaura Medical are in discussions with a number of large international organizations active in the Diabetes space with established infrastructure and market presence, concerning appointing one or more sub-distributors to cover European territories. DBE and Nemaura will share equally in all income and expenditure under the terms of the agreement.

Nemaura Medical, Inc. (NMRD), closed Monday's trading session at $2.79, down 0.36%, on 16,690 volume. The average volume for the last 60 days is 23,084 and the stock's 52-week low/high is $2.755/$7.00.

Tofutti Brands, Inc. (TOFB)

Market Exclusive, Zacks, and MarketWatch reported on Tofutti Brands, Inc. (TOFB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Tofutti Brands,  Inc. develops and distributes a complete line of dairy-free products. Its products are available across the United States and in more than 30 countries. Tofutti Brands’ products serve the needs of millions of people who are allergic or intolerant to dairy, diabetic, kosher or vegan, as well as those who want to have a healthier low-fat diet.  Established in 1981, Tofutti Brands is headquartered in Cranford, New Jersey.

All Tofutti Brands products are certified Kosher Parve. This means that none of the Company’s products ever contain any dairy whatsoever. This means no milk by-products either, such as casein, whey, skim milk powder, or dairy lactic acid.

The Company sells greater than 50 milk-free foods. These include frozen desserts, cheese products,  and prepared frozen dishes. Tofutti Brands’ product line includes dairy-free ice cream pints, Tofutti Cutie® sandwiches, and novelty bars.

Pertaining to wholesale and/or food service, Premium Tofutti frozen dessert is available in 3 gallon containers. Tofutti Better Than Cream Cheese, Tofutti Better Than Ricotta Cheese, Tofutti Better Than Mozzarella Cheese, and Tofutti Better Than Sour Cream are available in an assortment of bulk sizes. These include 30 lb. blocks, 5 lb. containers, and 1 oz. portion controlled cups (cream cheese only).

In addition, Tofutti Brands has an increasing array of prepared foods. These include Pizza Pizzaz® and Mintz's Blintzes® - all made with Tofutti's milk-free cheeses, including Better Than Cream Cheese® and Sour Supreme®. Tofutti dairy free cheeses, frozen desserts, as well as frozen foods can be found in major supermarkets and health food stores.

This past November, Tofutti Brands announced its results for the thirteen and thirty-nine week periods ended September 30, 2017. Net Income for the thirteen weeks ended September 30, 2017 grew to $323,000 or $0.06 per share (basic and diluted). This is in comparison to Net Income of $32,000, or $0.01 per share (basic and diluted), for the thirteen weeks ended October 1, 2016.

Net Income for the thirty-nine weeks ended September 30, 2017 was $420,000, or $0.08 per share (basic and diluted). This is in comparison to Net Income of $356,000, or $0.07 per share (basic and diluted), for the thirty-nine weeks ended October 1, 2016.

Mr. David Mintz, Tofutti Brands’ Chairman and Chief Executive Officer, stated in November, "I am pleased with the increase in sales of our vegan cheese products during the thirteen and the thirty-nine week periods ended September 30, 2017 and our improved profitability in 2017. We achieved these improved results despite the headwinds encountered in our frozen dessert product production and sales. Our continuing focus on reducing operating expenses and improving margins are evident in our improved gross profit margin in the thirteen weeks ended September 30, 2017…”

Tofutti Brands, Inc. (TOFB), closed Monday's trading session at $2.54, up 1.60%, on 2,228 volume with 13 trades. The average volume for the last 60 days is 5,236 and the stock's 52-week low/high is $1.55/$3.04.

Isodiol International, Inc. (ISOLF)

OTC Markets, Wealth Daily, Investopedia, Stockhouse, and InvestorsHub reported on Isodiol International, Inc. (ISOLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Isodiol International, Inc. specializes in the development of pharmaceutical and wellness products. The Company’s growth strategy includes the development of over-the-counter (OTC) and pharmaceutical drugs, and expanding its phytoceutical portfolio. Isodiol is continuing global expansion into Latin America, Asia, and Europe. A worldwide CBD innovator, Isodiol International has its corporate headquarters in Vancouver, British Columbia. Be Trū Wellness (Be Tru) is a wholly-owned subsidiary of Isodiol International.

Isodiol specializes in hemp based health and wellness products and the development of pharmaceutical CBD delivery methods. It additionally specializes in the manufacturing of a pure, natural CBD as an Active Pharmaceutical Ingredient (API) for use in finished pharmaceutical products (FPPs).

The Company is the market leader in pharmaceutical grade phytochemical compounds. It is also the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol produces raw ingredients, consumer packaged goods including dietary supplements, food and beverages, skin care, and pharmaceutical products for the international healthcare market. Regarding raw ingredients, Isodiol develops natural phytoceutical derivatives and delivery technologies. 

Concerning consumer products, the Company develops its own family of product brands for retail sale. Isodiol also develops white label products and brands for wholesale customers. Pertaining to pharmaceuticals, Isodiol supplies raw phytoceutical ingredients. 

Isodiol International has its ImmunAG™. This product is the market’s first non-cannabis cannabidiol (CBD) product derived from the hops plant. This is a time-released tablet. The ImmunAG tablet does not dissolve in the stomach. It dissolves in the lower intestine, therefore creating greater bioactivity. 

Isodiol International has acquired global licensing rights for IsoDerm™ and five other proprietary pharmaceutical compounds to be delivered by the patented Direct Effects Technology™. This is a back of the neck delivery system from its developer Dr. Ronald Aung-Din, MD.

Two of Isodiol International’s flagship medical products, Isoderm and Purodiol, were recently featured at the International League Against Epilepsy in Sao Paola, Brazil. The congress was hosted by neurology experts from around the world.

Today, Isodiol International announced unaudited May 2018 consolidated revenue numbers of $3,316,646 CDN.

Mr. Marcos Agramont, Chief Executive Officer of Isodiol International, stated, “May was a historic month for revenues. These numbers legitimize what we have accomplished over the last several months, particularly with the acquisitions of KURE Corp and BSPG Laboratories, Ltd. Shareholders can expect audited financials for the period of April 1, 2017 - March 31, 2018 to be available on July 30th, 2018.”

Isodiol International, Inc. (ISOLF), closed Monday's trading session at $0.484348, up 5.29%, on 573,376 volume with 173 trades. The average volume for the last 60 days is 199,814 and the stock's 52-week low/high is $0.093/$1.69.

RedHawk Holdings Corp. (IDNG)

Innovative Marketing, Penny Stock General, Stock Shock and Awe, PennyStocks24, TopPennyStockMovers, Real Pennies, Greenbackers, Fast Money Alerts, Mad Money Picks, The Observer, and Hot Stock Profits reported previously on RedHawk Holdings Corp. (IDNG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

RedHawk Holdings Corp. is a diversified holding company headquartered in Lafayette, Louisiana. The Company, by way of its subsidiaries, engages in the sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services.

RedHawk Holdings was formerly Independence Energy Corp. RedHawk’s subsidiaries are RedHawk Medical, EcoGen Europe, RedHawk Energy Corp., and RedHawk Land & Hospitality. RedHawk Holdings lists on the OTCQB.

RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System. This System is an innovative, closed cabinet, nominal dose transmission full body x-ray scanner.

Via its RedHawk Medical Products business unit, RedHawk Holdings sells WoundClot Surgical - Advanced Bleeding Control; the Sharps and Needle Destruction Device (SANDD™); the Carotid Artery Digital Non-Contact Thermometer, and Zonis®.

RedHawk Medical Products UK Limited is a specialist medical device company. It delivers unique product solutions to healthcare markets in the United Kingdom (UK), Europe and the Middle East.

EcoGen Europe’s commitment is to healthcare and the NHS. Its dedication is to securing savings across the drug budget in primary care. This is while providing innovation to drive patient care in the acute setting.

RedHawk’s financial services revenue is from brokerage services earned in association with debt placement services and investments in oil and gas exploration and production. The Company’s real estate leasing revenues come from different commercial properties under long-term lease. In addition, its real estate investment unit holds limited liability company interest in varied commercial restoration projects in Hawaii.

RedHawk Holdings has acquired a stake in Tigress Energy Partners. RedHawk agreed to acquire up to a 25 percent interest in Marlin USA Energy Partners, LLC, the minority owner of Tigress Energy Partners, LLC (TEP). The majority ownership of TEP is held by Tigress Holdings, LLC, a limited liability company majority-owned by Cynthia DiBartolo, Chief Executive Officer of Tigress Financial Partners LLC (TFP).

Recently, RedHawk Holdings announced its results for the three-month period ended September 30, 2017, as the Company continues to methodically build and develop its branded generic pharmaceutical and medical device business.

For the three-month period ended September 30, 2017, RedHawk Holdings reported a smaller than expected consolidated net loss attributable to RedHawk of $55,464 on gross revenues of $67,893 versus a consolidated net loss attributable to RedHawk of $193,561 on gross revenues of $499,280 for the comparable three-month period ended September 30, 2016.

RedHawk Holdings Corp. (IDNG), closed Monday's trading session at $0.006, up 11.63%, on 58,000 volume with 6 trades. The average volume for the last 60 days is 111,210 and the stock's 52-week low/high is $0.0032/$0.021.

TechCare Corp. (TECR)

InvestorsHub, OTC Markets, Investing, Barchart, Stockhouse, 4-Traders, GuruFocus, PennyStockTweets, Investors Hangout, and Emerging Growth reported on TechCare Corp. (TECR), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTCQB, TechCare Corp. has an innovative delivery platform that uses vapor technology for natural health and beauty treatments. The Company engages in the design, development, and commercialization of this unique delivery platform utilizing vaporization of different natural, plant-based compounds, to enable a wide assortment of treatment solutions. A technology enterprise, TechCare is based in New York, New York.

TechCare has a strategic partnership agreement with HoMedics, one of the world's leading brands in health and wellness products. HoMedics will manufacture, market, and distribute TechCare's Novokid products in the United States, Canada, Brazil, Argentina, Colombia, and Costa Rica. The products will be co-branded as HoMedics products powered by TechCare.

Novokid consists of a portable device that vaporizes TechCare's all-natural, plant-based solution contained in a disposable capsule. It comes with a proprietary head cap.

Novokid is the first of its type home use device. It presents a scientifically proven solution to eliminate lice, super lice, and eggs. Novokid is 100 percent natural, plant-based and pesticide-free. Novokid uses a proprietary vapor-based delivery platform. TechCare’s Novokid has received CE Mark approval as a CLASS I Medical Device.

Novokid uses a simple 10 minute dry treatment. The treatment requires no rinsing or washing. The treatment is fast, dry, and clean.

Furthermore, it is easily administered at home or while mobile. In addition, Novokid can be used as a maintenance and preventative treatment if used regularly.

Last month, TechCare announced that it signed its first distribution agreement with MWMedical B.V. for TechCare's Novokid lice treatment device, which addresses a $1.8 billion international market, and a European market estimated to exceed $500 million. MWMedical is a foremost distributor of medical devices in the Netherlands.

This multi-year agreement grants the distributor exclusive distribution rights in the Netherlands in consideration of minimum purchase commitments. The distributor has placed its first order of Novokid's products, 2,500 kits. They will be available in the Netherlands this month. The Netherlands represents the first success for TechCare among 28 European countries that the Company can sell to following the receipt of CE Approval.

Zvi Yemini, TechCare’s Chairman, said, "TechCare is delighted to announce its first agreement for Novokid with MWMedical to provide TechCare's leading technology with the broad representation of this organization in Netherlands. We are proud that after a wide-ranging evaluation, MWMedical has selected TechCare's technology. Beginning in February, the Dutch market will now have wide access to the superior Novokid lice treatment device."

TechCare Corp. (TECR), closed Monday's trading session at $0.53, up 89.29%, on 3,270 volume with 3 trades. The average volume for the last 60 days is 3,140 and the stock's 52-week low/high is $0.02/$0.75.

Lucara Diamond Corp. (LUCRF)

Penny Stock Tweets, Dividend Investor, Mining Feeds, Barchart, Marketbeat, InvestorsHub, ProInvestor, InvestorPoint, Insider Financial, Stockhouse, CapitalCube, MarketWatch, The Street, 4-Traders, Investors Hangout, Stockwatch, and Wallmine reported on Lucara Diamond Corp. (LUCRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lucara Diamond Corp. is a diamond mining company engaging in the acquisition, exploration, development, and operation of diamond properties in Africa. It is a foremost independent producer of large exceptional quality Type IIa diamonds from its 100 percent owned Karowe Mine in Botswana. The Company is a member of the Lundin Group of Companies.

Lucara Diamond is based in Vancouver, British Columbia. It has an experienced Board and Management team with wide-ranging diamond development and operations expertise.

The Karowe Diamond Mine in Botswana has been in production since 2012. It is one of worlds' leading producers of large, Type IIA diamonds in excess of 10.8 carats. This includes the historic 1,109 carat Lesedi La Rona (second largest gem diamond ever recovered) and the 813 carat Constellation (sold for a record US$63.1 million).

From the Karowe Diamond Mine 158 diamonds have sold for greater than US$1 million each (total value in excess of US$600 M). A PFS is taking place on Karowe underground with the potential to extend the mine-life to 2036.

Lucara Diamond also has its 100 percent owned Clara Diamond Solutions Corp. This is a secure, digital sales platform. It utilizes proprietary analytics together with cloud and blockchain technologies to modernize the existing diamond supply chain, boosting efficiencies, unlocking value and ensuring diamond origin from mine to finger. Commercialization is on course for Q3, 2018. On March 2, 2018, Lucara Diamond announced that it closed its acquisition of Clara Diamond Solutions.

Historically, Lucara Diamond has held Regular Stone Tenders (RSTs) and Exceptional Stone Tenders (ESTs). RSTs represent the majority of the Company’s run of mine production, held approximately 4 times per year.

This past April, Lucara Diamond announced the recovery of a 327 carat, top white gem diamond from its Karowe Diamond Mine in Botswana.  Eight diamonds greater than 100 carats have now been recovered at the Karowe Diamond Mine since the beginning of 2018. This includes the 472 carat diamond announced earlier in April.

Lucara Diamond Corp. (LUCRF), closed Monday's trading session at $1.607, up 0.44%, on 67,370 volume with 56 trades. The average volume for the last 60 days is 48,487 and the stock's 52-week low/high is $1.515/$2.325.

The QualityStocks Company Corner

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Mobile devices have become the go-anywhere remote controls that turn on — and turn off — the world around us. Net Element, Inc. (NASDAQ: NETE) is a fintech innovator that helps keep the signals open between businesses and their customers in a pay-per-play, on-demand-type marketplace that may be virtually headquartered anywhere between a business district, the highway or someone’s back yard.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $7.83, up 5.81%, on 432,669 volume with 1,448 trades. The average volume for the last 60 days is 456,089 and the stock's 52-week low/high is $2.556/$33.51.

Recent News

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

What could be smarter than playing it safe, particularly when on the road as a driver? Driving defensively certainly helps, but, more often than expected, the unexpected happens. If only you could have had some inkling of what was coming. Well perhaps you can. Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX) is developing unique safety solutions for the automotive industry that provide real-time information to prevent accidents.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $2.9115, up 0.74%, on 25,162 volume with 36 trades. The average volume for the last 60 days is 25,601 and the stock's 52-week low/high is $2.44/$11.70.

Recent News

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Biopharmaceutical company Sunniva Inc. (CSE: SNN) (OTCQX: SNNVF) now seems set for a place in the sun. The North American provider of cannabis products and services announced on May 29, 2018, that its wholly owned subsidiary, Sunniva Medical Inc. (“SMI”), had received a Confirmation of Readiness (COR) notification from Health Canada.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $6.23, up 0.50%, on 78,394 volume with 131 trades. The average volume for the last 60 days is 35,297 and the stock's 52-week low/high is $5.86/$16.00.

Recent News

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is uniquely positioned to capitalize of the growth of two different markets in which it currently operates: dietary supplements and drug delivery systems. Two separate market research reports indicated recently that these sectors are expected to grow a projected 7.0 percent and 2.9 percent, respectively, over the next five years.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.0643, up 0.16%, on 33,000 volume with 6 trades. The average volume for the last 60 days is 16,665 and the stock's 52-week low/high is $0.002/$0.20.

Recent News

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (TSX: TGOD).

The Green Organic Dutchman Holdings Ltd. (TSX:TGOD) (US:TGODF) (the “Company” or “TGOD”) is pleased to announce that, effective June 8th, its wholly-owned subsidiary, Medican Organic Inc. has received its Cultivation License from Health Canada for the Company’s breeding facility in Salaberry-de-Valleyfield, Quebec (“Valleyfield”). The commissioning of this facility will allow the Company to create proprietary, organically grown strains of cannabis and cannabis seeds.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at

The Green Organic Dutchman (TSX: TGOD), closed the day's trading session at $7.55, off by 1.44%, 1,860,000 volume. The stock's 52-week low/high is $3.50/$8.279.

Recent News

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF)

The QualityStocks Daily Newsletter would like to spotlight First Cobalt Corp. (FTSSF).

First Cobalt Corp. (TSX-V: FCC) (ASX: FCC) (OTCQX: FTSSF) (the "Company") is pleased to announce a $9 million work program for the Iron Creek Project in Idaho, USA, which it acquired on June 4, 2018. The Company intends to publish a mineral resource estimate by October 2018 and complete an additional 30,000 metres of drilling designed to double the mineralized zone along strike beyond the area drilled in 2017.

First Cobalt Corp. (TSX.V: FCC) (OTCQX: FTSSF), with headquarters in Canada, is the largest land owner in the Cobalt Camp in Ontario with control of over 10,000 hectares (nearly 25,000 acres) of prospective land and 50 historic cobalt/silver mines. The company’s assets include a mill and the only permitted cobalt extraction refinery in North America capable of producing battery material, providing an integrated solution for cobalt projects. First Cobalt began drilling in the historic Cobalt Camp in 2017 and seeks to build shareholder value through new discovery and growth opportunities.

First Cobalt’s 2018 $C7 million drilling program, which includes testing different styles of mineralized areas throughout the Cobalt Camp in more than 10 past-producing mines known to contain cobalt, is a significant expansion over its 2017 exploration activities. The company received positive test drill results from the Bellellen mine location, with early results confirming the presence of high-grade cobalt and nickel, prompting First Cobalt to increase its drilling program at that site. A prospecting sampling program of existing muckpiles around the camp’s historic mines, trenches, pits and surrounding bedrock could provide an early production scenario.

First Cobalt Corp. is moving quickly to leverage its potential against an economic background that estimates global consumption for refined cobalt is set to grow at an average rate of approximately 5 percent per annum for the next 10 years. The electric vehicle market, in particular, is driving this sector since more than 50 percent of the world’s current production of cobalt is used in the manufacture of rechargeable lithium-ion batteries. The global lithium-ion battery market, as estimated by Zion Market Research, indicates the value at around USD $31 billion in 2016 and is expected to generate revenue of nearly USD $68 billion by end of 2022, growing at a compound annual growth rate of slightly above 17 percent.

First Cobalt is embracing innovation in the mining sector, utilizing a digital compilation of 100-plus years of mining and geological data spanning the historically prolific Cobalt Mining Camp’s lifespan. First Cobalt’s management team is also assessing the ability of artificial intelligence to accelerate the discovery cycle. As a member of the Mineral Exploration Research Centre (MERC) and Metal Earth Project, First Cobalt conducts regional geophysical surveys for geological interpretation of structures controlling cobalt-silver mineralization.

The company’s clear pathway to production and cash flow generation includes being one of only four fully permitted cobalt extraction refineries in Canada with significant material and processing infrastructure on site. With the price of cobalt increasing significantly and its importance in the growing battery market underpinning a strong long-term demand forecast, First Cobalt Corp. and its mining interests are primed for success.

First Cobalt Corp. President and CEO Trent Mell, a mining executive and capital markets professional with extensive international transactional experience, is joined by a team of reputable and seasoned deal-makers, mine builders and mine operators with decades of global experience in exploration, business development, geoscience, engineering and finance.

First Cobalt Corp. (FTSSF), closed the day's trading session at $0.50, off by 7.18%, on 298,702 volume with 137 trades. The average volume for the last 60 days is 133,299 and the stock's 52-week low/high is $0.375/$1.3041.

Recent News

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

CannabisNewsAudio announces the Audio Press Release (APR) titled "Diversity Leads to Growth in Flourishing Cannabinoid Industries," featuring Marijuana Company of America Inc. (OTC Pink: MCOA). To hear the NetworkNewsAudio version, visit To read the original editorial, visit

Marijuana Company of America Inc. (MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.044, off by 6.38%, on 10,531,831 volume with 520 trades. The average volume for the last 60 days is 5,551,821 and the stock's 52-week low/high is $0.0188/$0.0728.

Recent News

Hammer Fiber Optic Holdings Corp. (OTCQB: HMMR)

The QualityStocks Daily Newsletter would like to spotlight Hammer Fiber Optic Holdings Corp. (HMMR).

Hammer Fiber Optic Holdings Corp. (HMMR), with headquarters in New Jersey, is a telecommunications company investing in the future of wireless technology. The company’s holdings include Hammer Fiber Optic Investments, Ltd., D/B/A Hammer Fiber, an Internet Service Provider (ISP) that offers internet, voice, video and data services in New Jersey as well as carrier services in Philadelphia and New York. Hammer Fiber serves residential and small business markets with high-capacity broadband, voice and video through direct fiber as well as its wireless fiber platform – Hammer Wireless® AIR technology.

Hammer Fiber recently completed the initial development phase of its advanced LTE fixed wireless system, which was designed and built upon its successfully deployed wireless technology suite. The expansion allows Hammer Fiber to add ultra-high capacity cellular broadband applications to its product portfolio including wholesale services such as backhaul support for cellular network operators. Designed to complement Hammer Fiber’s core business of home residential service, the company expects this latest innovation to help position Hammer Fiber as a leader in future 5G technology. The company intends to leverage the Fixed LTE system in conjunction with its already deployed Fixed Wireless DOCSIS 3.1 system to deliver on one of its core promises, to deliver high capacity broadband to markets across the country at dramatically lower cost than traditional wireline methods, including fiber. Live field testing of the new system begins in early 2018 in the U.S. with service availability to follow later in the year.

Hammer Fiber has also expanded its IaaS (Infrastructure-as-a-Service) cloud services to include support for the cryptocurrency and blockchain industry. Interested companies will be able to host their products over Hammer Fiber’s robust and modern server infrastructure, fiber network architecture and data center presence in some of the most secure locations in the New York, New Jersey and Philadelphia regions. Hammer Fiber’s servers feature best-in-class computing power, designed to allow enterprise businesses to reap the benefits of utilizing a cloud-based system without the massive cost of establishing or maintaining a corporate data center.

“Distributed architecture infrastructure, such as those utilized by blockchain entities mining cryptocurrencies or other new vertical markets utilizing blockchain technology, are growing exponentially and we are poised to fulfill a critical but fundamental need of this explosive new industry,” said Mark Stogdill, CEO of Hammer Fiber. “The distributed ledger architectures that blockchains are built on require secure and robust data processing networks, highly scalable power generation and a reliable fiber optic backbone infrastructure linking up data centers worldwide for them to exist, and that is what we at Hammer Fiber do really well.”

Hammer Fiber seeks to achieve its vision by employing an extremely qualified group of business professionals with diverse backgrounds and successful track records from a variety of related industries. HMMR’s seasoned leadership team combines startup expertise with a consummate understanding of the regional competitive telecommunications landscape in sales, marketing, engineering, construction and business development.

Hammer Fiber Optic Holdings Corp. (HMMR), closed the day's trading session at $1.38, up 13.11%, on 522,860 volume with 677 trades. The average volume for the last 60 days is 20,918 and the stock's 52-week low/high is $0.882/$48.00.

Recent News

Pivot Pharmaceuticals Inc. (PVOTF)

The QualityStocks Daily Newsletter would like to spotlight Pivot Pharmaceuticals Inc. (PVOTF).

Pivot Pharmaceuticals Inc. (OTCQB: PVOTF), based in Vancouver, Canada, is an emerging biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that provide novel treatments for unmet healthcare needs. Pivot’s recent acquisition of BiPhasix ™ Transdermal Drug Delivery technology for the delivery of cannabinoids (CBD) to patients provides the answer for an age-old problem associated with cannabinoid-based therapies: the lack of a robust smoke-less delivery mechanism.

Research into the bioavailability of cannabinoid-based therapeutics shows that rates of absorption vary greatly between smoking cannabis to an orally-consumed product, with a difference noted even between individuals. Cannabinoids are degraded in the stomach and smoking may not appeal to patients for health or lifestyle reasons. Topical delivery, while a better alternative, has suffered from weak formulation issues. Transdermal cannabinoid delivery, on the other hand, could provide a better alternative route since it reduces side effects and bypasses other absorption issues. In addition, transdermal delivery provides the benefit of enabling patients to access a steady stream of medication over a prolonged period with fewer side effects.

Pivot Pharmaceutical’s newly created subsidiary, Pivot Green Stream Health Solutions Inc. (“Pivot Green Stream”), will focus on improving the bioavailability of cannabinoid-based and pharmaceuticals. BiPhasix™ has been tested in FDA and EMA approved human clinical trials, which have shown the delivery system enhances the bioavailability of many drugs and improves clinical outcomes. Pivot Green Stream is tasked with developing several natural health products containing cannabinoids (CBD) that can receive a Health Canada Natural Health Product (NHP) designation. This marketing method ensures a shorter development cycle and faster revenue generation opportunities.

Pivot Pharmaceuticals Inc., which has positioned itself as a growing and crucial vertical in the cannabis industry, represents a compelling opportunity in the biotechnology field. The company’s plans include working with Licensed Producers (LP) and Licensed Dealers (LD) to bring newer therapies to patients. The company has also applied to list on the Canadian Stock Exchange (CSE).

The global medical marijuana market is expected to reach a value of $55.8 billion by 2025, according to a new report by Grand View Research, Inc. The growing number of states and countries gaining approval for using cannabis in therapeutic applications is expected to continue driving the market forward.

Pivot Pharmaceuticals has assembled a highly experienced management team, bringing together a wealth of clinical, commercial, product development and financial experience. Among the many healthcare targets in Pivot’s pipeline are cancer supportive care, pain and inflammation, women’s sexual dysfunction, dermatology and eye disease.

Pivot Pharmaceuticals Inc. (PVOTF), closed the day's trading session at $0.3954, up 1.75%, on 82,883 volume with 50 trades. The average volume for the last 60 days is 139,250 and the stock's 52-week low/high is $0.047/$2.46.

Recent News


The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL Inc. (OTC: NUGL), is a search engine and online directory for the marijuana industry. NUGL’s database includes listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands. The company focuses on leading the evolution in business relations, development and organic data in the cannabis industry with metasearch technology.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $1.04, up 4.00%, on 122,679 volume with 96 trades. The average volume for the last 60 days is 101,754 and the stock's 52-week low/high is $0.405/$1.80.

Recent News

Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

Zenosense, Inc. (ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.306, off by 2.86%, on 126,945 volume with 36 trades. The average volume for the last 60 days is 135,918 and the stock's 52-week low/high is $0.15/$0.895.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.